PURPOSE: To compare the pathologic complete response (pCR) rate and relapse-free survival (RFS) and overall survival (OS) after neoadjuvant systemic chemotherapy (NST) in patients with breast cancer with and without deleterious BRCA1 and BRCA2 mutations. PATIENTS AND METHODS: A total of 317 women who underwent BRCA genetic testing and were treated with NST for breast cancer between 1997 and 2009 were included in the study. The Kaplan-Meier product-limit method was used to estimate RFS and OS rates. Logistic regression models were fit to determine the associations between BRCA status, pCR, and survival. RESULTS: Fifty-seven (18%) and 23 (7%) patients had BRCA1 and BRCA2 mutations, respectively. Twenty-six (46%) of 57 BRCA1 carriers achieved a pCR, compared with three (13%) of 23 BRCA2 carriers and 53 (22%) of 237 BRCA noncarriers (P < .001). In the multivariate logistic model, BRCA1 status (odds ratio [OR] = 3.16; 95% CI, 1.55 to 6.42; P = .002), estrogen receptor (ER) negativity (OR = 1.96; 95% CI:1.05 to 3.65; P = .03) and concurrent trastuzumab use (OR = 4.18; 95% CI, 2.04 to 8.57; P < .001) remained as independent significant predictors for a pCR. At a median follow-up of 3.2 years, 69 patients (22%) experienced a disease recurrence or death. No significant differences were noted in survival outcomes with respect to BRCA status and type of NST received. However, among BRCA1 carriers, patients who achieved a pCR had better 5-year RFS (P = .001) and OS (P = .01) rates than patients who did not. CONCLUSION: BRCA1 status and ER negativity are independently associated with higher pCR rates in patients with breast cancer. Overall prognosis of breast cancer in BRCA carriers is similar to sporadic breast cancers.
PURPOSE: To compare the pathologic complete response (pCR) rate and relapse-free survival (RFS) and overall survival (OS) after neoadjuvant systemic chemotherapy (NST) in patients with breast cancer with and without deleterious BRCA1 and BRCA2 mutations. PATIENTS AND METHODS: A total of 317 women who underwent BRCA genetic testing and were treated with NST for breast cancer between 1997 and 2009 were included in the study. The Kaplan-Meier product-limit method was used to estimate RFS and OS rates. Logistic regression models were fit to determine the associations between BRCA status, pCR, and survival. RESULTS: Fifty-seven (18%) and 23 (7%) patients had BRCA1 and BRCA2 mutations, respectively. Twenty-six (46%) of 57 BRCA1 carriers achieved a pCR, compared with three (13%) of 23 BRCA2 carriers and 53 (22%) of 237 BRCA noncarriers (P < .001). In the multivariate logistic model, BRCA1 status (odds ratio [OR] = 3.16; 95% CI, 1.55 to 6.42; P = .002), estrogen receptor (ER) negativity (OR = 1.96; 95% CI:1.05 to 3.65; P = .03) and concurrent trastuzumab use (OR = 4.18; 95% CI, 2.04 to 8.57; P < .001) remained as independent significant predictors for a pCR. At a median follow-up of 3.2 years, 69 patients (22%) experienced a disease recurrence or death. No significant differences were noted in survival outcomes with respect to BRCA status and type of NST received. However, among BRCA1 carriers, patients who achieved a pCR had better 5-year RFS (P = .001) and OS (P = .01) rates than patients who did not. CONCLUSION:BRCA1 status and ER negativity are independently associated with higher pCR rates in patients with breast cancer. Overall prognosis of breast cancer in BRCA carriers is similar to sporadic breast cancers.
Authors: Aman U Buzdar; Vicente Valero; Nuhad K Ibrahim; Deborah Francis; Kristine R Broglio; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Sonja E Singletary; Kelly K Hunt; Aysegul A Sahin; Francisco Esteva; William F Symmans; Michael S Ewer; Thomas A Buchholz; Gabriel N Hortobagyi Journal: Clin Cancer Res Date: 2007-01-01 Impact factor: 12.531
Authors: D Stoppa-Lyonnet; Y Ansquer; H Dreyfus; C Gautier; M Gauthier-Villars; E Bourstyn; K B Clough; H Magdelénat; P Pouillart; A Vincent-Salomon; A Fourquet; B Asselain Journal: J Clin Oncol Date: 2000-12-15 Impact factor: 44.544
Authors: P O Chappuis; L Kapusta; L R Bégin; N Wong; J S Brunet; S A Narod; J Slingerland; W D Foulkes Journal: J Clin Oncol Date: 2000-12-15 Impact factor: 44.544
Authors: M Colleoni; I Minchella; G Mazzarol; F Nolè; G Peruzzotti; A Rocca; G Viale; L Orlando; G Ferretti; G Curigliano; P Veronesi; M Intra; A Goldhirsch Journal: Ann Oncol Date: 2000-08 Impact factor: 32.976
Authors: Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Richard D Kennedy; Jennifer E Quinn; Paul B Mullan; Patrick G Johnston; D Paul Harkin Journal: J Natl Cancer Inst Date: 2004-11-17 Impact factor: 13.506
Authors: Soley Bayraktar; Angelica M Gutierrez-Barrera; Diane Liu; Tunc Tasbas; Ugur Akar; Jennifer K Litton; E Lin; Constance T Albarracin; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Banu K Arun Journal: Breast Cancer Res Treat Date: 2011-08-10 Impact factor: 4.872
Authors: Jennifer K Litton; Marion E Scoggins; Kenneth R Hess; Beatriz E Adrada; Rashmi K Murthy; Senthil Damodaran; Sarah M DeSnyder; Abenaa M Brewster; Carlos H Barcenas; Vicente Valero; Gary J Whitman; Jill Schwartz-Gomez; Elizabeth A Mittendorf; Alastair M Thompson; Thorunn Helgason; Nuhad Ibrahim; Helen Piwnica-Worms; Stacy L Moulder; Banu K Arun Journal: J Clin Oncol Date: 2019-08-28 Impact factor: 44.544
Authors: S Bayraktar; A M Gutierrez-Barrera; H Lin; N Elsayegh; T Tasbas; J K Litton; N K Ibrahim; P K Morrow; M Green; V Valero; D J Booser; G N Hortobagyi; B K Arun Journal: Clin Exp Metastasis Date: 2013-02-01 Impact factor: 5.150
Authors: Priyanka Sharma; Sara López-Tarruella; José Angel García-Saenz; Qamar J Khan; Henry L Gómez; Aleix Prat; Fernando Moreno; Yolanda Jerez-Gilarranz; Agustí Barnadas; Antoni C Picornell; María Del Monte-Millán; Milagros González-Rivera; Tatiana Massarrah; Beatriz Pelaez-Lorenzo; María Isabel Palomero; Ricardo González Del Val; Javier Cortés; Hugo Fuentes-Rivera; Denisse Bretel Morales; Iván Márquez-Rodas; Charles M Perou; Carolyn Lehn; Yen Y Wang; Jennifer R Klemp; Joshua V Mammen; Jamie L Wagner; Amanda L Amin; Anne P O'Dea; Jaimie Heldstab; Roy A Jensen; Bruce F Kimler; Andrew K Godwin; Miguel Martín Journal: Clin Cancer Res Date: 2018-07-30 Impact factor: 12.531